3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
41
Lung Neoplasms
11
Lymphoma, Large-Cell, Anaplastic
8
Neoplasm Metastasis
7
Multiple Myeloma
6
Lymphoma
6
Neoplasms
5
Colorectal Neoplasms
4
Adenocarcinoma
4
Uveal Melanoma
3
Neuroblastoma
3
Melanoma
3
Hematologic Neoplasms
3
Granuloma, Plasma Cell
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Glioma
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Interventions
Docetaxel
3
Carboplatin
3
motexafin gadolinium
2
figitumumab
2
cemiplimab
2
alpha-2'-deoxythioguanosine
2
Paclitaxel
2
vandetanib
1
temoporfin
1
tanespimycin
1
brigatinib
1
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Radiosurgery
1
Pemetrexed
1
Oxaliplatin
1
Gemcitabine
1
Everolimus
1
Erlotinib Hydrochloride
1
Crizotinib
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Large Cell
×
Crizotinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA